The confirmatory trial showed limited side effects relative to physician's choice of chemotherapy.
For certain women with recurrent ovarian cancer, results presented early today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago confirm that mirvetuximab soravtansine offers improved progression-free survival (PFS) and overall survival (OS) with fewer side effects.
Results from MIRASOL (NCT04209855) offer positive results for this newly approved treatment, described as an antibody microtubule inhibitor conjugate—the first in ovarian cancer. Mirvetuximab soravtansine (Elahere, Immunogen) received accelerated FDA approval in November 2022 based on results from SORAYA for women with platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. The indication was for women with 1-3 prior treatments.
“MIRASOL is the confirmatory, global randomized phase 3 trial that is poised to result in global approvals,” said lead investigator Kathleen N. Moore, MD, MS, associate director of clinical research and co-director of the Cancer Therapeutics Program at the Stephenson Cancer Center at the University of Oklahoma in Oklahoma City.
Speaking in a press briefing ahead of her presentation this morning, Moore said MIRASOL showed that mirvetuximab soravtansine offered patients improved levels of both survival and safety compared with previous standards of care.
“We’ll show you there were less grade 3 or higher treatment emergent adverse events, less serious adverse events, and markedly fewer discontinuations from assigned therapy,” she said. “We see no alopecia and less peripheral neuropathy than seen with the closest comparative, which would be paclitaxel,” a standard chemotherapy.
Study results. MIRASOL evaluated 453 women patients with platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. After a median follow-up of 13.1 months, results showed:
Mirvetuximab soravtansine targets folate receptor-alpha, which is overexpressed on a variety of epithelial-derived cancer cells. The drug binds to the receptor, leading to cell death. “This is the first antibody drug conjugate approved in ovarian cancer, the only biomarker selected therapy available for platinum resistant ovarian cancer, and only the second biomarker directed therapy, after PARP inhibitors, for ovarian cancer,” Moore said. “These are data we consider to be practice changing,” she said.
Moore’s enthusiasm stems in part from the grim statistics that surround ovarian cancer. In 2023, there will be an estimated 19,710 new cases and 13,270 deaths from ovarian cancer just in the United States. If the cancer spreads to distant sites, as was the case with MIRASOL, then 5-year survival rates are 30%. Due to the lack of a widespread screening method, more than 70% of people annually are diagnosed at this advanced stage.
The therapy is being evaluated in earlier lines of treatment, Moore said.
An ASCO commentator shared her assessment of the importance of the results. “Mirvetuximab soravtansine has fewer serious side effects, especially those that can lead to stopping treatment, compared to standard chemotherapies for patients with platinum-resistant ovarian cancer. This, coupled with the overall survival advantage, demonstrates progress and offers hope for these patients,” said Merry Jennifer Markham, MD, of the University of Florida.
Reference
Moore KN, Angelergues A, Konecny GE, et al. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. J Clin Oncol. 2023;41 (suppl 17):abstr LBA5507.
Just as it is important for retail analysts to understand the choices their customers make and why they may choose not to purchase a specific item, so is it important for the specialty pharmacy industry to understand the actions of prescribers and how the often inefficient prior authorization process affects patient outcomes.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More